| 0.54 -0.079 (-12.76%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 0.84  |
1-year : | 0.99 |
| Resists | First : | 0.72 |
Second : | 0.85 |
| Pivot price | 0.66 |
|||
| Supports | First : | 0.5 |
Second : | 0.42 |
| MAs | MA(5) : | 0.62 |
MA(20) : | 0.65 |
| MA(100) : | 0.6 |
MA(250) : | 0.6 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 4.6 |
D(3) : | 8.3 |
| RSI | RSI(14): 38.5 |
|||
| 52-week | High : | 1.16 | Low : | 0.25 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ORGS ] has closed below the lower bollinger band by 13.1%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ ORGS ] is to continue within current trading range. Bollinger Bands are 21% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.62 - 0.63 | 0.63 - 0.63 |
| Low: | 0.5 - 0.51 | 0.51 - 0.52 |
| Close: | 0.53 - 0.54 | 0.54 - 0.55 |
Orgenesis Inc., a biotech company, focusing on cell and gene therapies worldwide. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed POCare therapeutics that are processed and produced in closed automated POCare technology systems across a collaborative POCare network. It focuses on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care for treatment of the patient. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is based in Germantown, Maryland.
Thu, 27 Jun 2024
Orgenesis Inc. expands equity incentive plan by 9 million shares - Investing.com
Mon, 04 Mar 2024
Orgenesis Inc.'s (NASDAQ:ORGS) Price Is Right But Growth Is Lacking After Shares Rocket 119% - Simply Wall St
Mon, 28 Aug 2023
Orgenesis Inc (ORGS): A Deep Dive into Its Performance Potential - Yahoo Finance
Wed, 23 Aug 2023
Orgenesis (ORGS): A Value Trap in Disguise? - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 47 (M) |
| Held by Insiders | 2.919e+007 (%) |
| Held by Institutions | 29.3 (%) |
| Shares Short | 205 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -4.017e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -6 % |
| Return on Assets (ttm) | 333.3 % |
| Return on Equity (ttm) | -41.9 % |
| Qtrly Rev. Growth | 529000 % |
| Gross Profit (p.s.) | -0.57 |
| Sales Per Share | -263.92 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -1.4 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -12 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | -0.82 |
| Dividend | 0 |
| Forward Dividend | 272350 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|